Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Operating Expenses (2016 - 2025)

Organogenesis Holdings has reported Operating Expenses over the past 10 years, most recently at $431.9 million for Q4 2025.

  • Quarterly results put Operating Expenses at $431.9 million for Q4 2025, up 270.91% from a year ago — trailing twelve months through Dec 2025 was $671.4 million (up 47.68% YoY), and the annual figure for FY2025 was $519.5 million, up 7.48%.
  • Operating Expenses for Q4 2025 was $431.9 million at Organogenesis Holdings, up from $36.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for ORGO hit a ceiling of $431.9 million in Q4 2025 and a floor of -$134.5 million in Q4 2023.
  • Median Operating Expenses over the past 5 years was $82.0 million (2022), compared with a mean of $91.9 million.
  • Biggest five-year swings in Operating Expenses: tumbled 268.79% in 2023 and later soared 270.91% in 2025.
  • Organogenesis Holdings' Operating Expenses stood at $75.5 million in 2021, then increased by 5.53% to $79.7 million in 2022, then tumbled by 268.79% to -$134.5 million in 2023, then soared by 186.57% to $116.4 million in 2024, then soared by 270.91% to $431.9 million in 2025.
  • The last three reported values for Operating Expenses were $431.9 million (Q4 2025), $36.3 million (Q3 2025), and $113.6 million (Q2 2025) per Business Quant data.